Biotech Values

[biomaven0]

>>how releasing interim result improperly could bias final result

It's pretty easy to imagine scenarios where this happens.

For example, assume one particular subgroup is doing particularly poorly on the drug and some of the docs involved discover this. It's easy to see how they might subtly encourage (perhaps even unknowingly) their patients in that subgroup to drop out.

Signals to patients in a weight-loss trial are particularly important given the high level of drop-outs in any long-term trial.

Peter